A photo of Charles Quinn.

Medical Director, Pediatric Sickle Cell Program

Director, Erythrocyte Diagnostic Laboratory

Professor, UC Department of Pediatrics



Board Certified

Best Doctors logo

My Biography & Research


Dr. Quinn conducts patient-oriented and translational research in sickle cell disease and thalassemia. He is the medical director of the Pediatric Sickle Cell Disease Program and the medical director of the Erythrocyte Diagnostic Laboratory at Cincinnati Children’s Hospital. He is also the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.

Clinical Interests

Sickle cell disease; thalassemia; hemoglobinopathies; genetics of hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; hereditary spherocytosis (HS); hereditary xerocytosis (HX); immune thrombocytopenia (ITP).

Research Interests

Identifying the causes of the cardiomyopathy and nephropathy of sickle cell disease and identifying new treatments for these complications; direct measurement of red blood cell turnover (rate of hemolysis); MRI methods for the quantitation of tissue iron; new agents for immune thrombocytopenia (ITP).

Academic Affiliation

Professor, UC Department of Pediatrics

Clinical Divisions

Cancer and Blood Diseases, Sickle Cell and Hemoglobin Disorders, Cerebrovascular

Research Divisions

Hematology, Cancer and Blood Diseases

My Locations

My Education

MD: University of Texas Southwestern Medical Center, Dallas, TX, 1994.

MS: University of Texas Southwestern Medical Center, Dallas, TX, 2008.

Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.

Fellowship: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.

Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.

My Publications

Selected Publication

Left atrial dysfunction in sickle cell anemia is associated with diffuse myocardial fibrosis, increased right ventricular pressure and reduced exercise capacity. Alsaied, T; Niss, O; Tretter, JT; Powell, AW; Chin, C; Fleck, RJ; Cnota, JF; Malik, P; Quinn, CT; Nagueh, SM; et al. Scientific Reports. 2020; 10.

Diastolic dysfunction is associated with exercise impairment in patients with sickle cell anemia. Alsaied, T; Niss, O; Powell, AW; Fleck, RJ; Cnota, JF; Chin, C; Malik, P; Quinn, CT; Taylor, MD. Pediatric Blood and Cancer. 2018; 65.

Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial. Quinn, CT; Saraf, SL; Gordeuk, VR; Fitzhugh, CD; Creary, SE; Bodas, P; George, A; Raj, AB; Nero, AC; Terrell, CE; et al. American Journal of Hematology. 2017; 92:E520-E528.

Association between diffuse myocardial fibrosis and diastolic dysfunction in sickle cell anemia. Niss, O; Fleck, R; Makue, F; Alsaied, T; Desai, P; Towbin, JA; Malik, P; Taylor, MD; Quinn, CT. Blood. 2017; 130:205-213.

Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia. Quinn, CT; Smith, EP; Arbabi, S; Khera, PK; Lindsell, CJ; Niss, O; Joiner, CH; Franco, RS; Cohen, RM. American Journal of Hematology. 2016; 91:1195-1201.

Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology. Bakeer, N; James, J; Roy, S; Wansapura, J; Shanmukhappa, SK; Lorenz, JN; Osinska, H; Backer, K; Huby, A; Shrestha, A; et al. Proceedings of the National Academy of Sciences of the United States of America. 2016; 113:E5182-E5191.

Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease. Niss, O; Quinn, CT; Lane, A; Daily, J; Khoury, PR; Bakeer, N; Kimball, TR; Towbin, JA; Malik, P; Taylor, MD. JACC: Cardiovascular Imaging. 2016; 9:243-252.

Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Karkoska, K; Todd, K; Niss, O; Clapp, K; Fenchel, L; Kalfa, TA; Malik, P; Quinn, CT; Ware, RE; McGann, PT. Pediatric Blood and Cancer. 2021; 68.

Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. Hood, AM; Strong, H; Nwankwo, C; Johnson, Y; Peugh, J; Mara, CA; Shook, LM; Brinkman, WB; Real, FJ; Klein, MD; et al. JMIR Research Protocols. 2021; 10.

Mobile health use predicts self-efficacy and self-management in adolescents with sickle cell disease. Hood, AM; Nwankwo, C; Walton, A; McTate, E; Joffe, N; Quinn, CT; Britto, MT; Peugh, J; Mara, CA; Crosby, LE. Translational Behavioral Medicine. 2021.